Polymorphisms in xenobiotic conjugation and disease predisposition

Toxicology Letters

Volumn 102-103, Issue , 1998, Pages 173-183

  Brockmöller, Jürgen ^a   Cascorbi, Ingolf ^a   Kerb, Reinhold ^a   Sachse, Christoph ^a   Roots, Ivar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Arylamine N acetyltransferase; Cancer; Cytochrome P450; Disease susceptibility; Gene polymorphism; Glutathione S transferase

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; PHENACETIN O DEETHYLASE; POLYCYCLIC AROMATIC HYDROCARBON; TOBACCO SMOKE;

AGE; BLADDER CANCER; CANCER RISK; CONFERENCE PAPER; DISEASE PREDISPOSITION; DRUG CONJUGATION; ENZYME ACTIVITY; ENZYME INDUCTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUNG CANCER; PRIORITY JOURNAL; RISK; RISK FACTOR; SMOKING; TOBACCO; XENOBIOTIC METABOLISM;

NICOTIANA TABACUM;

EID: 17144471201     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(98)00304-X     Document Type: Conference Paper

References (64)

1. Alexandrie, A.K., Sundberg, M.I., Seidegård, J., Tornling, G., Rannug, A., 1994. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis 15, 1785-1790.
2. Bell, D.A., Taylor, J.A., Paulson, D.F., Robertson, C.N., Mohler, J.L., Lucier, G.W., 1993. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J. Natl. Cancer Inst. 85, 1159-1164.
3. Bell, D.A., Badawi, A.F., Lang, N.P., Ilett, K.F., Kadlubar, F.F., Hirvonen, A., 1995. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1* 10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res. 55, 5226-5229.
4. Bicho, M.P., Breitenfeld, L., Carvalho, A.A., Manso, C.F., 1988. Acetylation phenotypes in patients with bladder carcinoma. Ann. Rev. Genet. 31, 167-171.
5. Brockmöller, J., Gross, D., Kerb, R., Drakoulis, N., Roots, I., 1992. Correlation between trans-stilbene oxide-glutathione conjugation activity and the deletion mutation in the glutathione 5-transferase class mu gene detected by polymerase chain reaction. Biochem. Pharmacol. 43, 647-650.
6. Brockmöller, J., Kerb, R., Drakoulis, N., Nitz, M., Roots, I., 1993. Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls. Cancer Res. 53, 1004-1011.
7. Brockmöller, J., Kerb, R., Drakoulis, N., Staffeldt, B., Roots, I., 1994. Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. Cancer Res. 54, 4103-4111.
8. Brockmöller, J., Cascorbi, I., Kerb, R., Roots, I., 1996a. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res. 56, 3915-3925.
9. Brockmöller, J., Kaiser, R., Kerb, R., Cascorbi, I., Jaeger, V., Roots, I., 1996b. Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P53 mutations in bladder cancer. Pharmacogenetics 6, 535-545.
10. Cartwright, R., 1984. Epidemiological studies on N-acetylation and C-center ring oxidation in neoplasia. In: Omenn, G., Gelboin, H. (Eds.), Genetic Variability in Responses to Chemical Exposure, vol. 16. Cold Spring Harbor Laboratory, Cold Spring Harbor, pp. 359-365.
11. Cartwright, R.A., Glashan, R.W., Rogers, H.J., 1982. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 2, 842-845.
12. Cascorbi, I., Drakoulis, N., Brockmöller, J., Maurer, A., Sperling, K., Roots, I., 1995. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am. J. Hum. Genet. 57, 581-592.
13. Cascorbi, I., Brockmöller, J., Roots, I., 1996. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res. 56, 4965-4969.
14. Case, R.A.M., Hosker, M.E., McDonald, D.B., Pearson, J.T., 1954. Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. Part I. The role of aniline, benzidine, alpha-naphthylamine, and beta-naphthylamine. Br. J. Ind. Med. 11, 75-104.
15. Daly, A.K., Thomas, D.J., Cooper, J., Pearson, W.R., Neal, D.E., Idle, J.R., 1993. Homozygous deletion of gene for glutathione 5-transferase M1 in bladder cancer. Br. Med. J. 307, 481-482.
16. Evans, D.A., Eze, L.C., Whibley, E.J., 1983. The association of the slow acetylator phenotype with bladder cancer. J. Med. Genet. 20, 330-333.
17. Gaedigk, A., Spielberg, S.P., Grant, D.M., 1994. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 4, 142-153.
18. Grant, D.M., Hughes, N.C., Janezic, S.A., 1997. Human acetyltransferase polymorphisms. Mutat. Res. 376, 61-70.
19. Hanssen, H.P., Agarwal, D.P., Goedde, H.M., 1985. Association of N-acetyltransferase polymorphism and environmental factors with bladder carcinogenesis. Study in a north German population. Eur. Urol. 11, 263-266.
20. Hassett, C., Aicher, L., Sidhu, J.S., Omiecinski, C.J., 1994. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants [published erratum appears in Hum. Mol. Genet. 1994 Jul., 3(7), 1214]. Hum. Mol. Genet. 3, 421-428.
21. Hayashi, S., Watanabe, J., Kawajiri, K., 1992. High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transferase genes. Jpn. J. Cancer Res. 83, 866-870.
22. Heckbert, S.R., Weiss, N.S., Hornung, S.K., Eaton, D.L., Motulsky, A.G., 1992. Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. J. Natl. Cancer Inst. 84, 414-422.
23. Hill, A., 1967. Statistical evidence and interference. In: Hill, A. (Ed.), Principles of Medical Statistics. Oxford University Press, Oxford, pp. 302-325.
24. Hirvonen, A., Husgafvel Pursiainen, K., Anttila, S., Vainio, H., 1993. The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis 14, 1479-1481.
25. Hirvonen, A., Nylund, L., Kociba, P., Husgafvel Pursiainen, K., Vainio, H., 1994. Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers [published erratum appears in Carcinogenesis 1994 Aug., 15(8), 1767]. Carcinogenesis 15, 813-815.
26. Kaisary, A., Smith, P., Jaczq, E., 1987. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res. 47, 5488-5493.
27. Karakaya, A.E., Cok, I., Sardas, S., Gogus, O., Sardas, O.S., 1986. N-Acetyltransferase phenotype of patients with bladder cancer. Hum. Toxicol. 5, 333-335.
28. Kato, S., Bowman, E.D., Harrington, A.M., Blomeke, B., Shields, P.G., 1995. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo [see comments] [published erratum appears in J Natl Cancer Inst 1996 Nov. 6, 88(21), 1595]. J. Natl. Cancer Inst. 87, 902-907.
29. Katoh, T., Inatomi, H., Nagaoka, A., Sugita, A., 1995. Cytochrome P4501A1 gene polymorphism and homozygous deletion of the glutathione S-transferase M1 gene in urothelial cancer patients. Carcinogenesis 16, 655-657.
30. Kawajiri, K., Nakachi, K., Imai, K., Watanabe, J., Hayashi, S., 1993. The CYP1A1 gene and cancer susceptibility. Crit. Rev. Oncol. Hematol. 14, 77-87.
31. Ketterer, B., Harris, J.M., Talaska, G., 1992. The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ. Health Perspect. 98, 87-94.
32. Kihara, M., Kihara, M., Noda, K., 1994. Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis 15, 415-418.
33. Ladero, J.M., Kwok, C.K., Jara, C., 1985. Hepatic acetylator phenotype in bladder cancer patients. Ann. Clin. Res. 17, 96-99.
34. Lafuente, A., Pujol, F., Carretero, P., Villa, J.P., Cuchi, A., 1993. Human glutathione S-transferase mu (GST mu) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. Cancer Lett. 68, 49-54.
35. Lin, H.J., Han, C.Y., Bernstein, D.A., Hsiao, W., Lin, B.K., Hardy, S., 1994. Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis 15, 1077-1081.
36. London, S.J., Daly, A.K., Cooper, J., Navidi, W.C., Carpenter, C.L., Idle, J.R., 1995. Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. J. Natl. Cancer Inst. 87, 1246-1253.
37. Lower, G.M., Jr., Nilsson, T., Nelson, C.E., Wolf, H., Gamsky, T.E., Bryan, G.T., 1979. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ. Health Perspect. 29, 71-79.
38. Lower, G., 1983. Molecular epidemiology of arylamine-induced urinary bladder cancer: some theoretical considerations. In: Weber, W., Hein, D., Litwin, A., Lower, G. (Eds.), Relationship of Acetylator Status to Isoniazid Toxicity, Lupus Erythematosus and Bladder Cancer, pp. 3086-3097.
39. MacLeod, S., Tang, Y.-M., Yokoi, T., Kamataki, T., Doublin, S., Lawson, B., Massengill, J., Kadlubar, F., Lang, N., 1998. The role of recently discovered genetic polymorphism in the regulation of the human CYP1A2 gene. In: Proceedings of the American Association for Cancer Research, pp. 396.
40. Matas, N., Thygesen, P., Stacey, M., Risch, A., Sim, E., 1997. Mapping AAC1, AAC2 and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a region frequently deleted in tumours. Cytogenet. Cell. Genet. 77, 290-295.
41. McGlynn, K.A., Rosvold, E.A., Lustbader, E.D., et al., 1995. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc. Natl. Acad. Sci. USA. 92, 2384-2387.
42. Miller, M.E., Cosgriff, J.M., 1983. Acetylator phenotype in human bladder cancer. J. Urol. 130, 65-66.
43. Mommsen, S., Aagaard, J., 1986. Susceptibility in urinary bladder cancer: acetyltransferase phenotypes and related risk factors. Cancer Lett. 32, 199-205.
44. Nakachi, K., Imai, K., Hayashi, S., Kawajiri, K., 1993. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res. 53, 2994-2999.
45. Nazar Stewart, V., Motulsky, A.G., Eaton, D.L., 1993. The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res. 53, 2313-2318.
46. Okkels, H., Sigsgaard, T., Wolf, H., Autrup, H., 1996. Glutathione S-transferase mu as a risk factor in bladder tumours. Pharmacogenetics 6, 251-256.
47. Persson, I., Johansson, I., Ingelman Sundberg, M., 1997. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem. Biophys. Res. Commun. 231, 227-230.
48. Risch, A., Wallace, D.M., Bathers, S., Sim, E., 1995. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum. Mol. Genet. 4, 231-236.
49. Rojas, M., Bouvier G., Alexandrov, K., Cascorbi, I., Brockmöller, J., Likhachev, A., Pozharisski, K., Bouvier, G., Auburtin, G., Mayer, L., Koop-Schneider, A., Roots, I., Bartsch, H., 1998. High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from subjects with combined CYP1A1 MspI/MspI-GSTM1* 0/0 genotypes. Pharmacogenetics 8, 109-118.
50. Roots, I., Drakoulis, N., Brockmöller, J., Janicke, I., Cuprunov, M., Ritter, J., 1989. Hydroxylation and acetylation phenotypes as genetic risk factors in certain malignancies. In: Kato, R., Estabrook, R.W., Cayen, M.N. (Eds.), Xenobiotic Metabolism and Disposition. Taylor and Francis, London, pp. 499-506.
51. Ryberg, D., Hewer, A., Phillips, D.H., Haugen, A., 1994. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res. 54, 5801-5803.
52. Sachse, C., Brockmöller, J., Bauer, S., Roots, I., in press. Functional significance of a CA polymorphism in intron 1 of the cytochrome P450 1A2 (CYP1A2) gene tested with caffeine. Br. J. Clin. Pharmacol.
53. Schlesselman, J., 1982. Case-Control Studies. Oxford University Press, New York, Oxford.
54. Seidegård, J., Pero, R.W., Miller, D.G., Beattie, E.J., 1986. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis 7, 751-753.
55. Seidegård, J., Pero, R.W., Markowitz, M.M., Roush, G., Miller, D.G., Beattie, E.J., 1990. Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow up study. Carcinogenesis 11, 33-36.
56. Vaury, C., Laine, R., Noguiez, P., 1995. Human glutathione S-transferase M1 null genotype is associated with a high inducibility of cytochrome P450 1A1 gene transcription. Cancer Res. 55, 5520-5523.
57. Vineis, P., Bartsch, H., Caporaso, N., Harrington, A.M., Kadlubar, F.F., Landi, M.T., Malaveille, C., Shields, P.G., Skipper, P., Talaska, G., Tannenbaum, S.R., 1994. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 369, 154-156.
58. Warholm, M., Alexandrie, A.-K., Carstensen, U., 1998. Biomarkers in relation to PAH exposure in aluminium smelter workers. Toxicol. Lett. 95, 187.
59. Wiencke, J.K., Kelsey, K.T., Lamela, R.A., Toscano, W.A., Jr., 1990. Human glutathione S-transferase deficiency as a marker of susceptibility to epoxide-induced cytogenetic damage. Cancer Res. 50, 1585-1590.
60. Woodhouse, K.W., Adams, P.C., Clothier, A., Mucklow, J.C., Rawlins, M.D., 1982. N-acetylation phenotype in bladder cancer. Hum. Toxicol. 1, 443-445.
61. Yu, M., Ross, R., Chan, K., 1995. Glutathione S-transferase M1 genotype affects aminobiphenyl-hemoglobin adduct levels in white, black and Asian men in Los Angeles, California. J. Natl. Cancer Inst. 86, 712-716.
62. Zhang, Z.Y., Fasco, M.J., Huang, L., Guengerich, F.P., Kaminsky, L.S., 1996. Characterization of purified human recombinant cytochrome P4501A1-Ile462 and -Val462: assessment of a role for the rare allele in carcinogenesis. Cancer Res. 56, 3926-3933.
63. Zhong, S., Howie, A.F., Ketterer, B., 1991. Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 12, 1533-1537.
64. Zhong, S., Wyllie, A.H., Barnes, D., Wolf, C.R., Spurr, N.K., 1993. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 14, 1821-1824.